Valentin Fuster, MD, PhD, president of Mount Sinai Heart and physician-in-chief of the Mount Sinai Hospital in New York City, said the trial was the first to show a therapy could prevent secondary adverse cardiovascular events in people who have previously had a heart attack, according to a news release.
The pill, which is approved in 25 countries but not the U.S., is composed of three active ingredients: acetylsalicylic acid, atorvastatin and ramipril. Its maker has submitted a drug approval application to the FDA.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
